GHK-Cu Peptide Research: Cognitive Aging Study Findings

A growing body of research is investigating whether endogenous peptides can meaningfully influence the biology of brain aging — and a newly published preclinical study adds an important layer of complexity to that question. A June 2026 study by Mazzola, Rosenfeld, Tucker, and colleagues, published in Research Square, found that GHK-Cu — a naturally occurring copper-binding peptide that declines with age — improved hippocampal-dependent learning in aged mice, but that the route and duration of administration produced strikingly different molecular outcomes. The findings suggest that how a gerotherapeutic is delivered may be just as important as whether it is delivered at all.

What This Study Found

Researchers administered GHK-Cu (15 mg/kg) to aged C57BL/6J mice (20–21 months old) using two different delivery methods: short-term intraperitoneal (IP) injection over five days, and longer-term intranasal (IN) administration over eight weeks. Cognitive performance was assessed using a hippocampal-dependent spatial navigation task, while molecular effects were evaluated through hippocampal immunohistochemistry and bulk RNA sequencing (Mazzola et al., 2026).

Both delivery routes produced measurable behavioral improvements, but the patterns differed. Intranasal GHK-Cu improved escape latency across multiple trials in both male and female mice (P < 0.05), suggesting a more consistent and sustained effect on spatial learning. Intraperitoneal dosing, by contrast, produced a transient improvement in males during the second trial only (P < 0.05), with no sustained effect and no significant improvement in females.

The molecular data revealed even more striking divergence. Intranasal treatment was associated with coordinated suppression of oxidative phosphorylation pathways in both sexes (male NES −5.44, female NES −4.20; FDR < 0.0001), along with suppression of MYC target pathways and, in females, attenuation of PI3K-AKT-mTOR signaling — a pathway broadly implicated in cellular aging. These findings suggest that longer-term intranasal exposure may engage what the researchers describe as an aging-biology suppression program.

The IP route told a different story at the molecular level. Rather than suppressing metabolic and growth signaling, IP treatment activated oxidative phosphorylation (female NES 4.97, FDR < 0.001), DNA repair pathways (NES 5.58, FDR < 0.001), and MYC targets — a profile consistent with acute stress-response and cellular repair engagement. Immunohistochemistry also differed: intranasal treatment increased synaptophysin (a marker of synaptic density) in females (P < 0.001) and decreased GFAP (a marker of astrocyte reactivity) in both sexes (P < 0.01), while IP treatment reduced TGF-β, GFAP, and MCP-1 in males and decreased the senescence marker p21 in females (P < 0.0001).

The researchers concluded that GHK-Cu can improve hippocampal-dependent learning through distinct biological mechanisms depending on how it is administered — and that functional cognitive benefit does not require a single molecular pathway.

Clinical Significance

These findings carry meaningful implications for how researchers and clinicians think about peptide-based interventions in the context of brain aging. GHK-Cu is an endogenous tripeptide (glycyl-L-histidyl-L-lysine complexed with copper) that the study notes declines naturally with age. Its known properties include regenerative and anti-inflammatory effects, and prior research has suggested roles in tissue repair and gene expression modulation. What this study adds is evidence — in an animal model — that the compound may also engage discrete aging-relevant biological programs in the hippocampus depending on how it is delivered.

The suppression of oxidative phosphorylation and mTOR signaling observed with intranasal delivery is particularly notable from a geroscience perspective. Both pathways are well-established contributors to cellular aging, and interventions that modulate them — such as rapamycin and caloric restriction — have been among the most studied longevity strategies in preclinical models. The study suggests that sustained intranasal GHK-Cu exposure may engage a related molecular profile, at least in aged mice.

Equally important is the study's documentation of sex-specific differences in both behavioral and molecular responses. Female mice did not respond to IP administration in the same way males did, and several molecular markers differed significantly between sexes across both delivery conditions. This underscores the importance of sex as a biological variable in aging research — a dimension that is still underrepresented in many preclinical studies.

It is critical to emphasize that this study was conducted entirely in mice, and as the researchers themselves note, human data are needed before any conclusions about clinical application can be drawn. Animal models of aging provide valuable mechanistic insights, but they do not always translate directly to human biology.

Current Access and Compliance Context

GHK-Cu is currently available through compounding pharmacies in some countries, and it appears in topical cosmetic formulations, though the delivery routes and concentrations used in those contexts differ substantially from those studied here. In the United States, peptides including GHK-Cu occupy a complex regulatory landscape. Access through licensed compounding pharmacies requires a valid prescription from a qualified healthcare provider, and the clinical use of peptides for anti-aging or cognitive applications remains an evolving area that is not yet supported by approved labeling indications.

The intranasal route studied here is of particular interest from an access standpoint because it is non-invasive and may offer improved central nervous system bioavailability compared to systemic administration — though this remains to be validated in human studies. Patients and clinicians interested in peptide-based interventions should be aware that the regulatory and evidence landscape is still developing, and that decisions about use should be made in consultation with a knowledgeable provider who can weigh individual risk-benefit considerations.

What Patients Should Know

If you are interested in peptide research and its potential relevance to cognitive aging, here are the key takeaways from this study to discuss with your healthcare provider:

Delivery route appears to matter significantly. The study suggests that intranasal and intraperitoneal administration of GHK-Cu produced different behavioral and molecular outcomes in aged mice. This finding implies that the way a compound is administered — not just whether it is administered — may shape its therapeutic profile. Translating this insight to human care will require clinical research.

Duration of exposure also appears relevant. The longer-term intranasal protocol (eight weeks) produced more consistent behavioral improvements across both sexes compared to the shorter IP protocol (five days). Duration of treatment is a factor that would need to be carefully studied and individualized in any future human trials.

Sex differences were observed. Males and females did not always respond to treatment the same way, both behaviorally and molecularly. If and when human trials are conducted, sex-stratified analyses will be important for understanding who may benefit from which approach.

This is preclinical research. The study was conducted in aged mice, and the researchers have not claimed that these results translate directly to humans. Cognitive aging in humans is more complex, and many promising preclinical findings have not replicated in clinical trials. Patients should approach this research with informed optimism rather than as established medical guidance.

Conclusion

The 2026 study by Mazzola and colleagues represents a meaningful contribution to preclinical aging research. By demonstrating that GHK-Cu can improve hippocampal-dependent learning in aged mice through two distinct molecular programs — each shaped by the route and duration of administration — the researchers have opened important questions about how delivery strategy should factor into the design of gerotherapeutic interventions. The divergence between an acute repair-activation profile (IP) and a sustained aging-biology suppression profile (IN) suggests that the same compound may serve different biological roles depending on how it reaches the brain.

While human data are needed before clinical conclusions can be drawn, findings like these help lay the scientific groundwork for future research. As the field of peptide medicine advances, working with a knowledgeable, licensed provider is essential for patients who want to explore these options responsibly.

To find a qualified provider with experience in peptide-based therapies, visit peptideassociation.org/find-a-doctor.

---

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The research discussed involves animal models, and findings may not apply to humans. Always consult a qualified, licensed healthcare provider before making any decisions about medications, supplements, or therapeutic interventions.

---

Citation (AMA format): Mazzola J, Rosenfeld M, Tucker M, et al. Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs. Research Square. June 2026. doi:10.21203/rs.3.rs-9520102/v1. PMID: 42245779.